Biology of adenovirus vectors with E1 and E4 deletions for liver- directed gene therapy

Journal of Virology

Volumn 70, Issue 12, 1996, Pages 8934-8943

  Gao, Guang Ping ^a   Yang, Yiping ^a   Wilson, James M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; GENE PRODUCT; VIRUS PROTEIN; VIRUS VECTOR;

ADENOVIRUS 5; ALPHA 1 ANTITRYPSIN DEFICIENCY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; GENE DELETION; GENE TRANSFER; HEMOPHILIA; HYPERLIPIDEMIA; LIVER; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENE; UREA CYCLE; VIRUS ISOLATION; VIRUS RECOMBINANT;

EID: 0029959867     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.70.12.8934-8943.1996     Document Type: Article

References (49)

1. Acsadi, G., H. Lochmuller, A. Jani, J. Huard, B. Massie, S. Prescott, M. Simoneau, B. J. Petrof, and G. Karpati. 1996. Dystrophin expression in muscles of mdx mice after adenovirus-mediated in vivo gene transfer. Hum. Gene Ther. 7:129-140.
2. Barr, D., J. Tubb, D. Ferguson, A. Scaria, A. Lieber, C. Wilson, J. Perkins, and M. Kay. 1995. Strain related variations in adenovirally mediated transgene expression from mouse hepatocytes in vivo: comparisons between immunocompetent and immunodeficient inbred strains. Gene Ther, 2:151-155.
3. Bridge, E., and G. Ketner. 1989. Redundant control of adenovirus late gene expression by early region 4. J. Virol. 63:631-638.
4. Connelly, S., J. M. Gardner, A. McClelland, and M. Kaleko. 1996. High-level tissue-specific expression of functional human factor VIII in mice. Hum. Gene Ther. 7:183-195.
5. Cutt, J. R., T. Shenk, and P. Hearing. 1987. Analysis of adenovirus early region 4-encoded polypeptides synthesized in productively infected cells. J. Virol. 61:543-552.
6. Dai, Y., E. Schwartz, D. Gu, W. Zhang, N. Sarvetnick, and I. Verma. 1995. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc. Natl. Acad. Sci. USA 92:1401-1405.
7. Dobner, T., N. Horikoshi, S. Rubenwolf, and T. Shenk. 1996. Blockage by adenovirus E4orf6 of transcriptional activation by the p53 tumor suppressor. Science 272:1470-1473.
8. Engelhardt, J., L. Litzky, and J. Wilson. 1994. Prolonged transgene expression in cotton rat lung with recombinant adenoviruses defective in E2a. Hum. Gene Ther. 5:1217-1229.
9. Fang, B., R. C. Eisensmith, H. Wang, M. A. Kay, R. E. Cross, C. N. Landen, G. Gordon, D. A. Bellinger, M. S. Read, P. C. Hu, K. M. Brinkhous, and S. L. C. Woo. 1995. Gene therapy for hemophilia B: host immunosuppression prolongs the therapeutic effect of adenovirus-mediated factor IX expression. Hum. Gene Ther. 6:1039-1044.
10. Ferrari, F. K., T. Samulski, T. Shenk, and R, J. Samulski. 1996. Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J. Virol. 70:3227-3234.
11. Fisher, K. J., G.-P. Gao, M. D. Weitzman, R. DeMatteo, J. F. Burda, and J. M. Wilson. 1996. Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis. J. Virol, 70:520-532.
12. Friedrich, G., and P. Soriano. 1991. Promoter traps in embryonic stem cells: a genetic screen to identify and mutate developmental genes in mice. Genes Dev. 5:1513-1523.
13. Herz, J., and R. Gerard. 1993. Adenovirus-mediated transfer of low density lipoprotein receptor gene acutely accelerates cholesterol clearance in normal mice. Proc. Natl. Acad. Sci. USA 90:2812-2816.
14. Huang, M. M., and P. Hearing. 1989. Adenovirus early region 4 encodes two gene products with redundant effects in lytic infection. J. Virol. 63:2605-2615.
15. Huang, M. M., and P. Hearing. 1989. The adenovirus early region 4 open reading frame 6/7 protein regulates the DNA binding activity of the cellular transcription factor, E2F, through a direct complex. Genes Dev. 3:1699-1710.
16. Ishibashi, S., M. Brown, J. Goldstein, R. Gerard, R. Hammer, and J. Herz. 1993. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J. Clin. Invest. 92:883-893.
17. Jaffe, H. A., G. Danel, G. Longenecker, M. Metzger, Y. Setoguchi, M. A. Rosenfeld, T. W. Gant, S. S. Thorgeirsson, L. D. Stratford-Perricaudet, M. Perricaudet, A. Pavirani, J. P. Lecocq, and R. G. Crystal. 1992. Adenovirus-mediated in vivo gene transfer and expression in normal rat liver. Nature Genet. 1:372-378.
18. Jooss, K., and J. M. Wilson. Unpublished data.
19. Jooss, K., Y. Yang, and J. M. Wilson. Cyclophosphamide diminishes inflammation and prolongs transgene expression following delivery of adenoviral vectors to mouse liver and lung. Hum. Gene Ther., in press.
20. Kay, M., F. Graham, F. Leland, and S. Woo. 1995. Therapeutic serum concentrations of human alpha-1-antitrypsin after adenoviral-mediated gene transfer into mouse hepatocytes. Hepatology 21:815-819.
21. Kay, M. A., C. N. Landen, S. R. Rothenberg, L. A. Taylor, F. Leland, S. Wiehle, B. Fang, D. Bellinger, M. Finegold, A. R. Thompson, M. Read, K. M. Brinkhous, and S. L. C. Woo. 1994. In vivo hepatic gene therapy: complete albeit transient correction of factor IX deficiency in hemophilia B dogs. Proc. Natl. Acad. Sci. USA 91:2353-2357.
22. Kleinberger, T., and T. Shenk. 1993. Adenovirus E4orf4 protein binds to protein phosphatase 2A, and the complex down regulates E1 A-enhanced junB transcription. J. Virol. 67:7556-7560.
23. Kozarsky, K., M. Grossman, and J. Wilson. 1993. Adenovirus-mediated correction of the genetic defect in hepatocytes from patients with familial hypercholesterolemia. Somatic Cell Mol. Genet. 19:449-45
24. Kozarsky, K., D. McKinley, L. Austin, S. Raper, L. Stratford-Perricaudet, and J. Wilson. 1994. In vivo correction of LDL receptor deficiency in the watanabe heritable hyperlipidemic rabbit with recombinant adenoviruses. J. Biol. Chem. 269:13695-13702.
25. Kozursky K. F., M. Donahee, K. Jooss, J. F. Strauss, and J. M. Wilson. 1996. Effective treatment of familial hypercholesterolemia in the mouse model using adenovirus-mediated transfer of the VLDL receptor gene. Nat. Genet. 13:54-62.
26. Krougliak, V., and F. L. Graham. 1995. Development of cell lines capable of complementing El, E4, and protein IX defective adenovirus type 5 mutants. Hum. Gene Ther. 6:1575-1586.
27. Li, Q., M. Kay, M. Finegold, L. Stratford-Perricaudet, and S. Woo. 1993. Assessment of recombinant adenoviral vectors for hepatic gene therapy. Hum. Gene Ther. 4:403-409.
28. Marton, M. J., S. B. Bairn, D. A. Ornelles, and T. Shenk. 1990. The adenovirus E4 17-kilodalton protein complexes with the cellular transcription factor E2F, altering its DNA-binding properties and stimulating EA-independent accumulation of E2 mRNA. J. Virol. 64:2345-2359.
29. Morsy, M. A., E. L. Alford, A. Bett, F. L. Graham, and C. T. Caskey. 1993. Efficient adenoviral-mediated ornithine transcarhamylase expression in deficient mouse and human hepatocytes. J. Clin. Invest. 92:1580-1586.
30. Muller, U., T. Kleinberger, and T. Shenk. 1992, Adenovirus E4orf4 protein reduces phosphorylation of c-Fos and EA proteins while simultaneously reducing the level of AP-I. J. Virol. 66:5867-5878.
31. Neill, S. D., C. Hemstrom, A. Virtanen, and J. R. Nevins. 1990. An adenovirus E4 gene product trans-activates E2 transcription and stimulates stable E2F binding through a direct association with E2F. Proc. Natl. Acad. Sci. USA 87:2008-2012.
32. Obert, S., R. J. O'Connor, S. Schmid, and P. Hearing. 1994. The adenovirus E4-6/7 protein transactivates the E2 promoter by inducing dimerization of a heteromeric E2F complex. Mol. Cell. Biol. 14:1333-1346.
33. Smith, T., M. Mehaffey, D. Kayda, J. Saunders, S. Yei, B. Trapnell, A. McClelland, and M. Kaleko. 1993. Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice. Nat. Genet. 5:397-402.
34. Tripathy, S. K., H. B. Black, E. Goldwasser, and J. M. Leiden. 1996. Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nat. Med. 2:545-550.
35. Van Ginkel, F., C. Liu, J. Simecka, J. Dong, T. Greenway, R. Frizzell, H. Kiyono, J. McGhee, and D. Pascual. 1995. Intratracheal gene delivery with adenoviral vector induces elevated systemic IgG and mucosal IgA antibodies to adenovirus and β-galactosidase. Hum. Gene Ther. 6:895-903.
36. Wang, Q., X.-C. Jia, and M. H. Finer. 1995. A packaging cell line for propogation of recombinant adenovirus vectors containing two lethal generegion deletions. Gene Ther. 2:775-783.
37. Weinberg, D. H., and G. Ketner. 1983. A cell line that supports the growth of a defective early region 4 deletion mutant of human adenovirus type 2. Proc. Natl. Acad. Sci. USA 80:5383-5386.
38. Yang, Y., H. Ertl, and J. Wilson. 1994. MHC class 1 restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1 deleted recombinant adenoviruses. Immunity 1:433-442.
39. Yang, Y., S. E. Haecker, Q. Su, and J. M. Wilson. Immunology of gene therapy with adenoviral vectors in mouse skeletal muscle. Hum. Mol. Genet., in press.
40. Yang, Y., K. U. Jooss, Q. Su, H. C, J. Ertl, and J. M. Wilson. 1996. Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Ther. 3:137-144.
41. Yang, Y., Q. Li, H. Ertl, and J. Wilson. 1995. Cellular and humoral immune responses to viral antigens create harriers to lung-directed gene therapy with recombinant adenoviruses. J. Virol. 69:2004-2015.
42. Yang, Y., F. Nunes, K. Berencsi, E. Furth, E. Gønczøl, and J. Wilson. 1994. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc. Natl. Acad. Sci. USA 91:4407-4411.
43. Yang, Y., F. Nunes, K. Berencsi, E. Gønczøl, J. Engelhardt, and J. Wilson. 1994. Inactivalion of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. Nature Genet. 7:362-369.
44. Yang, Y., Z. Xiang, H. C. J. Ertl, and J. M. Wilson. 1995. Upregulation of class I MHC antigens by interferon-γ is necessary for the T cell-mediated elimination of recombinant adenovirus infected hepatocytes in vivo. Proc. Natl. Acad. Sci. USA 92:7257-7261.
45. Ye, X., M. B. Robinson, M. L. Batshaw, E. E. Furth, I. Smith, and J. M. Wilson. 1996. Prolonged metabolic correction in adult ornithine transcarbamylase deficient mice with adenoviral vectors. J. Biol. Chem. 271:3639-3946.
46. Yeh, P., J.-F. Dedieu, C. Orsini, E. Vigne, P. Denefle, and M. Perricaudet. 1996. Efficient dual transcomplementation of adenovirus El and E4 regions from a 293-derived cell line expressing a minimal E4 functional unit. J. Virol. 70:559-565.
47. Yei, S., N. Mittereder, K. Tang, C. O'Sullivan, and B. C. Trapnell. 1994. Adenovirus-mediated gene transfer for cystic fibrosis: quantitative evaluation of repeated in vivo vector administration to the lung. Gene Ther. 1:192-200.
48. Yewdell, J. W., and J. R. Bennink. Immune responses to viruses. In D. D. Richman, R. J. Whitely. and F. G. Hayden (ed.), Clinical virology. Churchill Livingstone, Edinburgh.
49. Zsengeller, Z., S. Wert, W. Hull, X. Hu, S. Yei, B. Trapnell, and J. Whitsett. 1995. Persistence of replication-deficient adenovirus-mediated gene transfer in lungs of immune-deficient (nu/nu) mice. Human Gene Ther. 6:457-467.